Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cris Luengo"'
Autor:
Will Paces, Elliott Ergon, Elizabeth Bueche, G. Dave Young, Vitria Adisetiyo, Cris Luengo, Meredith James, Charles Caldwell, Dannah Miller, Morgan Wambaugh, Geoffrey Metcalf, Roberto Gianani
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract PD-L1 (22C3) checkpoint inhibitor therapy represents a mainstay of modern cancer immunotherapy for non-small cell lung cancer (NSCLC). In vitro diagnostic (IVD) PD-L1 antibody staining is widely used to predict clinical intervention efficacy
Externí odkaz:
https://doaj.org/article/fcfbd68415114c36b101185dfdc94015
Autor:
Will Paces, Rebecca Kim, Huong Nguyen, Roberto Gianani, Michael Argyres, Cris Luengo, Charles W. Caldwell, Bradley Long
Publikováno v:
Cancer Research. 80:3879-3879
PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in specifically identifying macrophages in PD-L1 stained tissues, but pathologists o
Autor:
Kelsey Weigel, Will Paces, Elliott Ergon, Jeni Caldara, Kile McFadden, Cris Luengo, Roberto Gianani, Bharathi Vennapusa
Publikováno v:
Cancer Research. 79:4918-4918
Understanding response to immunotherapy requires accurate and complete characterization of tumor-associated immune cells in order to fully contextualize the immuno-oncology biomarker expression. Current standard practices surrounding enumeration of b
Autor:
Cris Luengo Hendriks, Ziquan Yu, Antoine Lecocq, Teatske Bakker, Barbara Locke, Olle Terenius
Publikováno v:
University of Copenhagen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::809ea99c7f2c4c2bc8e8d8c8b4a42be7
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-188544
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-188544